Overview

SCT Plus Immune Therapy in Average Risk AML/MDS

Status:
Recruiting

Trial end date:
2023-12-01

Target enrollment:

Participant gender:

Summary

Allogeneic stem cell transplantation followed by targeted immune therapy with Gemtuzumab Ozogamicin (Mylotarg) will be given to patients with average risk AML or MDS.

Phase:

Phase 2

Details

Lead Sponsor:

New York Medical College

Treatments:

Gemtuzumab